Biopolymer-mediated suramin chemotherapy in the treatment of experimental brain tumours

REFERENCES

• Simpson JR, Horton J, Scott C, et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys 1993; 26: 239–44.
   PubMed Web of Science ®Google Scholar
• Plate KH, Risau W Angiogenesis in malignant gliomas. Glia 1995; 15: 339–47.
   PubMed Web of Science ®Google Scholar
• Dunn IF, Heese 0, Black PM. Growth factors in glioma angiogenesis: FGFs, PDGF, EGF, and TGFs. J Neurooncol 2000; 50: 121–37.
   Google Scholar
• Guo P, Hu B, Gu W, et al. Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothe-lial growth factor expression in tumor endothelia and by promoting pericyte recruitment. Am J Pathol 2003; 162: 1083–93.
   PubMed Web of Science ®Google Scholar
• Folkman J. Angiogenesis inhibitors generated by tumors. Mol Med 1995; 1: 120–2.
   PubMed Web of Science ®Google Scholar
• Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362: 841–4.
   PubMed Web of Science ®Google Scholar
• Leland P, Obiri N, Aggarwal BB, Puri RK. Suramin blocks binding of interleukin-4 to its receptors on human tumor cells and interleukin-4-induced mitogenic response. Oncol Res 1995; 7: 227–35.
   PubMedGoogle Scholar
• Schrell UM, Gauer S, Kiesewetter F, et al. Inhibition of proliferation of human cerebral meningioma cells by suramin: effects on cell growth, cell cycle phases, extracellular growth factors, and PDGF-BB autocrine growth loop. J Neurosurg 1995; 82: 600–7.
   PubMedGoogle Scholar
• Sullivan KA, Kim B, Buzdon M, Feldman EL. Suramin disrupts insulin-like growth factor-II (IGF-II) mediated auto-crine growth in human SH-SY5Y neuroblastoma cells. Brain Res 1997; 744: 199–206.
   PubMedGoogle Scholar
• Taylor CW, Lui R, Fanta P, Salmon SE. Effects of suramin on in vitro growth of fresh human tumors. J Natl Cancer Inst 1992; 84: 489–94.
   PubMed Web of Science ®Google Scholar
• Bocci G, Danesi R, Benelli U, et al. Inhibitory effect of suramin in rat models of angiogenesis in vitro and in vivo. Cancer Chemother Pharmacol 1999; 43: 205–12.
   PubMed Web of Science ®Google Scholar
• Gagliardi AR, Kassack M, Kreimeyer A, Muller G, Nickel P, Collins DC. Antiangiogenic and antiproliferative activity of suramin analogues. Cancer Chemother Pharmacol 1998; 41: 117–24.
   PubMed Web of Science ®Google Scholar
• Arbuck SG, Sorensen JM, Christian MC, Ho P, Pluda JM, Cheson BD. New drugs in non-Hodgkin's lymphoma. Ann Oncol 1997; 8 (Suppl 1): 119–28.
   PubMedGoogle Scholar
• Small EJ, Halabi S, Ratain MJ, et al. Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480. J Clin Oncol 2002; 20: 3369–75.
   PubMedGoogle Scholar
• Olson JJ, Polk DM, Reisner A. The efficacy and distribution of suramin in the treatment of the 9L gliosarcoma. Neurosurgery 1994; 34: 297–308.
   Google Scholar
• Takano S, Gately S, Engelhard H, Tsanaclis AM, Brem S. Suramin inhibits glioma cell proliferation in vitro and in the brain. J Neurooncol 1994; 21: 189–201.
   Google Scholar
• Bernsen HJ, Rijken PF, Peters JP, et al. Suramin treatment of human glioma xenografts; effects on tumor vasculature and oxygenation status. J Neurooncol 1999; 44: 129–36.
   PubMed Web of Science ®Google Scholar
• Pardridge WM. CNS drug design based on principles of blood-brain barrier transport. J Neurochem 1998; 70: 1781–92.
   PubMed Web of Science ®Google Scholar
• Tamargo RJ, Myseros JS, Epstein JI, Yang MB, Chasin M, Brem H. Interstitial chemotherapy of the 9L gliosarcoma: controlled release polymers for drug delivery in the brain. Cancer Res 1993; 53: 329–33.
   PubMed Web of Science ®Google Scholar
• Rhine WD, Hsieh DS, Langer R. Polymers for sustained macromolecule release: procedures to fabricate reproducible delivery systems and control release kinetics. J Pharm Sci 1980; 69: 265–70.
   Google Scholar
• Zhang RD, Price JE, Fujimaki T, Bucana CD, Fidler U. Differential permeability of the blood-brain barrier in experi-mental brain metastases produced by human neoplasms implanted into nude mice. Am J Pathol 1992; 141: 1115–24.
   Google Scholar
• Spigelman Z, Dowers A, Kennedy S, et al. Antiproliferative effects of suramin on lymphoid cells. Cancer Res 1987; 47: 4694–8.
   PubMedGoogle Scholar
• Horne MK, III, Stein CA, LaRocca RV, Myers CE. Circulating glycosaminoglycan anticoagulants associated with suramin treatment. Blood 1988; 71: 273–9.
   Google Scholar
• Bitton RJ, Figg WD, Venzon DJ, et al. Pharmacologic variables associated with the development of neurologic toxicity in patients treated with suramin. J Clin Oncol 1995; 13: 2223–9.
   PubMedGoogle Scholar
• Cole DJ, Ettinghausen SE, Pass HI, et al. Postoperative complications in patients receiving suramin therapy. Surgery 1994; 116: 90–5.
   PubMedGoogle Scholar
• La Rocca RV, Meer J, Gilliatt RW, et al. Suramin-induced polyneuropathy. Neurology 1990; 40: 954–60.
   PubMed Web of Science ®Google Scholar
• Saini M, Bellinzona M, Weichhold W, Samii M. A new xenograft model of primary central nervous system lymphoma. J Neurooncol 1999; 43: 153–60.
   PubMed Web of Science ®Google Scholar